IDMC recommends discontinuing Phase III of Axsome's AXS-02 for complex regional pain syndrome

Axsome Therapeutics Inc. (NASDAQ:AXSM) said an IDMC recommended discontinuing for futility the Phase III CREATE-1 trial of once-weekly oral AXS-02 (disodium zoledronate tetrahydrate) for six weeks to

Read the full 277 word article

User Sign In